Side-by-side · Research reference

SS-31vsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED9/43 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

SS-31

Cardiolipin-binding · Mitochondrial protective

40 mgDaily doseSzeto 2014

Phase 3Evidence levelSzilagyi 2009 Szeto 2014

~3 hrHalf-life

SQ · Abdomen · Once daily

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

SS-31

Testagen

Primary target

Cardiolipin in inner mitochondrial membraneSzeto 2014

Testicular tissue; proposed nuclear DNA interaction

Pathway

Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014 Szilagyi 2009

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

—

Unknown — no HPG axis data

Origin

Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

SS-31

Testagen

Standard dose

40 mg / day SQ (clinical trials)Szeto 2014

Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.

—

Frequency

Once daily

Once daily or alternate days

Lower / starter dose

5 mg / day (anecdotal)

—

Evidence basis

Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014 Szilagyi 2009

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

Indefinite for mitochondrial disease; cycled for healthspan use

—

Reconstitution

Bacteriostatic water

Sterile water or bacteriostatic saline

Timing

Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress

—

Half-life

~3 h plasma; tissue uptake longer

Unknown — likely minutes (short peptide)

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

04Side Effects & Safety

Parameter

SS-31

Testagen

Injection site reaction

Erythema, mild pruritus

—

GI symptoms

Nausea (uncommon)

—

Headache

Reported in some Phase 3 trials

—

Cardiovascular

Cardio-protective in studies; no signal of harm

—

Long-term safety

Phase 3 data over 24+ months; no major safety signalsSzeto 2014

Unknown — no long-term studies

Pregnancy / OB

Avoid — insufficient data

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Absolute Contraindications

SS-31

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Testagen

·Active testicular malignancy

Relative Contraindications

SS-31

·None established

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

SS-31

Testagen

1. Reconstitution

Add bacteriostatic water per label. Light-protected handling.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Morning fasted; pre-workout for exercise-augmented mitochondrial stress.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

29–31G, 4–8 mm insulin syringe.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

SS-31

+ MOTS-c

Moderate

View MOTS-c →

SS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.

SS-31: 5–10 mg SQ · daily morning
MOTS-c: 5 mg SQ · 2× per week pre-workout
Primary benefit: Mitochondrial preservation + biogenesis

Testagen

— no documented stacks